|
03/13/2010 11:00 PM
|
|
Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
|
Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC), a CSC Company (NYSE:CSC), presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter's Vero cell culture platform and does not contain an adjuvant or preservatives...
|
|
03/13/2010 11:00 PM
|
|
Genentech Provides Update On Phase III Study Of Avastin In Men With Late Stage Prostate Cancer
|
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S...
|
|
03/13/2010 11:00 PM
|
|
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
|
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC)...
|
|
03/13/2010 11:00 PM
|
|
Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint
|
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints...
|
|
03/13/2010 01:00 AM
|
|
Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer
|
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck KGaA/Oncothyreon's Stimuvax vaccine earns Decision Resources' proprietary clinical gold standard status in 2013 and 2018 for the treatment of locally advanced non-small-cell lung cancer...
|
|
03/13/2010 01:00 AM
|
|
Diabetes Experts Call For Early, Integrated Treatment Approach To Help Prevent Complications And Improve Patient Outcomes
|
Results from a new online survey of more than 300 practicing endocrinologists and family medicine physicians1 show that a large majority of physicians (83 percent)1 indicated that using a team of specialists early in the course of type 2 diabetes (T2D) treatment can help prevent serious T2D-related complications...
|
|
03/13/2010 12:00 AM
|
|
Seeking 'Next Generation' Treatment For Breast Cancer
|
Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes...
|
|
|
• Home
• FDA News
• Medicines
• Cancer
• Heart Disease
• Articles
|
|
03/12/2010 12:00 PM
|
|
Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug
|
Boxed warning added regarding reduced effectiveness of Plavix in poor metabolizers.
|
|
03/12/2010 10:00 AM
|
|
Counterfeit Polypropylene Surgical Mesh: Initial Communication
|
Various sizes of counterfeit flat sheets of polypropylene surgical mesh are being marketed in the United States labeled with the C. R. Bard/Davol brand name.
|
|
03/11/2010 12:45 PM
|
|
Baylis Medical Torflex Transseptal Guiding Sheath: Class I Recall
|
Sheath tip may break off and separate during heart procedures, causing a blockage that could lead to permanent injury and/or death.
|
|
03/11/2010 08:15 AM
|
|
Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
|
FDA review of available data have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.
|
|
03/11/2010 06:15 AM
|
|
Beckman Coulter UniCel DxC Synchron Clinical System – Ion Selective Electrode Flow Cell: Class I Recall
|
Incorrect sodium results may be caused by build-up of protein, bacteria, and sample tube additives in the ion selective electrode flow cell.
|
|
03/10/2010 01:20 PM
|
|
Abiomed AB5000 Circulatory Support System: Class I Recall
|
Device computer may shut down without an alarm, which can lead to serious injuries or death.
|
|
03/10/2010 09:50 AM
|
|
WinRho SDF (Rho(D) Immune Globulin Intravenous (Human): Risk of Intravascular Hemolysis
|
Cases of intravascular hemolysis and its complications have been reported in patients treated for immune thrombocytopenic purpura with WinRho.
|
|
03/08/2010 11:15 AM
|
|
Cardiac Science Automated External Defibrillators (Powerheart, Cardiovive, CardioLife, NK, Responder models): Class I Recall
|
UPDATED 03/08/2010: Recall classified as Class I, expanded list of affected models. Originally posted 02/09/2010
|
|
03/05/2010 09:20 AM
|
|
Thomas Medical Products, Inc., Transseptal Sheath Introducer Kits: Class I Recall
|
Sheath tip may break off and separate during heart procedures, causing a blockage that could lead to permanent injury and/or death.
|
|
03/03/2010 08:55 AM
|
|
Baxter HomeChoice and HomeChoice PRO Automated Peritoneal Dialysis Systems: Class I Recall
|
Reports of serious injuries and at least one death have been associated with increased Intraperitoneal Volume (IIPV), also known as overfill of the abdominal cavity.
|
|
|